CoChat

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

Open access

The DOI matches its Crossref record, with a small difference in title or year; 90 of the 90 references it cites were found in a registry or an index.

Abstract

Purpose: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma. Methods: Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31–68 years of age) were included. Treatment was with oral dabrafenib, 150 mg bid, trametinib, 2 mg/day, and HCQ, 400 mg to 600 mg bid. An ophthalmic examination, spectral domain optical coherence tomography, near-infrared and short-wavelength fundus autofluorescence, and static perimetry were performed at baseline, 1 month, and q/6 months after treatment. Results: There were no clinically significant ocular events; there was no ocular inflammation. The only medication-related change was a separation of the photoreceptor outer segment tip from the apical retinal pigment epithelium that could be traced from the fovea to the perifoveal retina noted in 9/11 (82%) of the patients. There were no changes in retinal pigment epithelium melanization or lipofuscin content by near-infrared fundus autofluorescence and short-wavelength fundus autofluorescence, respectively. There were no inner retinal or outer nuclear layer changes. Visual acuities and sensitivities were unchanged. Conclusion: BRAFi (trametinib) + MEKi (dabrafenib) + HCQ causes very frequent, subclinical separation of the photoreceptor outer segment from the apical retinal pigment epithelium without inner retinal changes or signs of inflammation. The changes suggest interference with the maintenance of the outer retinal barrier and/or phagocytic/pump functions of the retinal pigment epithelium by effective MEK inhibition.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000002027

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Cited by

See all 31

Metadata

Authors
Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., Mitnick, S., Huang, A., Nichols, C. W., Amaravadi, R. K., Kim, B. J., & Aleman, T. S.
Affiliations
  • Department of Ophthalmology, Scheie Eye Institute at the Perelman Center for Advanced Medicine, the
  • Abramson Cancer Center (US)
Corresponding author
  • Nti, Akosua A.
  • Serrano, Leona W.
  • Sandhu, Harpal S.
  • Uyhazi, Katherine E.
  • Edelstein, Ilaina D.
  • Zhou, Elaine J.
  • Bowman, Scott
  • Song, Delu
  • Nichols, Charles W.
  • Kim, Benjamin J.
Venue
Retina
Published
2019-03
Volume
39
Issue
3
Pages
502-513
ISSN
0275-004X (ISSN-L)
OpenAlex
W2783517192
Cited by
31
References
90
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 1
FWCI
4.02
Type
journal article
Language
en
Open access
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Heidelberg Engineering
  • National Eye Institute (K12EY015398, P30EY001583)
  • National Cancer Institute (P01CA114046, P50CA093372, R01CA198015, P50CA174523)
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular and Laser Science Research
Keywords
BRAF V600E melanoma, metastatic melanoma, dabrafenib, trametinib, hydroxychloroquine, ocular toxicity, photoreceptor outer segments, retinal pigment epithelium, fundus autofluorescence, optical coherence tomography
MeSH terms
Adult, Aged, Antineoplastic Agents, Enzyme Inhibitors, Female, Humans, Hydroxychloroquine, Imidazoles, Macula Lutea, Male, Melanoma, Middle Aged, Oximes, Photoreceptor Cells, Pyridones, Pyrimidinones, Retinal Diseases, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf, Retinal Pigment Epithelium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. https://app.cochat.ai/papers/10.1097/iae.0000000000002027
The paper
Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., Mitnick, S., Huang, A., Nichols, C. W., Amaravadi, R. K., Kim, B. J., & Aleman, T. S. (2019). FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina. https://doi.org/10.1097/iae.0000000000002027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.